TY - JOUR
T1 - The prevention and treatment of metabolic syndrome and high-risk obesity
AU - Molavi, Behzad
AU - Rasouli, Neda
AU - Kern, Philip A.
PY - 2006/9
Y1 - 2006/9
N2 - PURPOSE OF REVIEW: The prevalence of obesity is increasing at an alarming rate, and the obesity epidemic is driving the epidemic in type 2 diabetes. High-risk obesity is characterized by abdominal obesity with evidence of abnormal glucose and lipid metabolism, and a state of heightened inflammation. RECENT FINDINGS: With increasing body weight, lipid accumulation occurs not only in adipose tissue, but in other organs as well. This 'lipotoxicity' in liver, muscle, islets, and elsewhere may account for many of the features of the metabolic syndrome. Adipose tissue produces many proteins, some of which are inflammatory cytokines, and others of which are antiinflammatory or which improve insulin sensitivity. SUMMARY: The treatment of obesity requires the identification of the high-risk patient, and the institution of lifestyle measures with a long-term outlook, and an avoidance of heavily marketed fads. Current research will likely lead to improved medications in the future.
AB - PURPOSE OF REVIEW: The prevalence of obesity is increasing at an alarming rate, and the obesity epidemic is driving the epidemic in type 2 diabetes. High-risk obesity is characterized by abdominal obesity with evidence of abnormal glucose and lipid metabolism, and a state of heightened inflammation. RECENT FINDINGS: With increasing body weight, lipid accumulation occurs not only in adipose tissue, but in other organs as well. This 'lipotoxicity' in liver, muscle, islets, and elsewhere may account for many of the features of the metabolic syndrome. Adipose tissue produces many proteins, some of which are inflammatory cytokines, and others of which are antiinflammatory or which improve insulin sensitivity. SUMMARY: The treatment of obesity requires the identification of the high-risk patient, and the institution of lifestyle measures with a long-term outlook, and an avoidance of heavily marketed fads. Current research will likely lead to improved medications in the future.
KW - High-risk obesity
KW - Lipid
KW - Metabolic syndrome
KW - Prevention
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=33747071746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747071746&partnerID=8YFLogxK
U2 - 10.1097/01.hco.0000240586.76344.f5
DO - 10.1097/01.hco.0000240586.76344.f5
M3 - Review article
C2 - 16900012
AN - SCOPUS:33747071746
SN - 0268-4705
VL - 21
SP - 479
EP - 485
JO - Current Opinion in Cardiology
JF - Current Opinion in Cardiology
IS - 5
ER -